Form 4: Theravance Biopharma SVP Sells 24,000 Shares Under Pre-Arranged 10b5-1 Plan

Rhonda Farnum, SVP of Commercial and Medical Affairs at Theravance Biopharma, Inc., sold 24,000 ordinary shares for $11 per share, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Rhonda Farnum, the Senior Vice President of Commercial and Medical Affairs at Theravance Biopharma, Inc. (TBPH), reported a sale of company shares.
• The transaction involved the disposition of 24,000 ordinary shares.
• The shares were sold at a price of $11 per share.
• The sale occurred on June 2, 2025.
• Following this transaction, Ms. Farnum beneficially owns 336,918 ordinary shares directly.
• The transaction was executed in accordance with a Rule 10b5-1 trading plan established by Ms. Farnum on March 14, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the disclosure that it was executed under a pre-arranged 10b5-1 plan mitigates concerns that the sale is based on new, negative material information. It's a routine disclosure of a planned transaction.

Positives

• The sale was conducted under a Rule 10b5-1 plan, which indicates a pre-scheduled transaction rather than a reaction to immediate market conditions, potentially reducing negative market interpretation.

Negatives

• An insider selling a significant number of shares (24,000) can sometimes be perceived negatively by investors, as it might suggest a lack of confidence in the company's future prospects, although the 10b5-1 plan mitigates this to some extent.

Risks

• While the sale was pre-planned, significant insider selling can occasionally lead to negative market sentiment or increased scrutiny from investors regarding the company's outlook.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Management Comments

• The transaction was executed in accordance with the reporting person's 10b5-1 plan dated 03/14/2024.

Industry Context

This document is a standard insider trading disclosure (Form 4) and does not provide information directly related to broader industry trends or competitive landscape. It solely reports a change in beneficial ownership by a company executive.

Stakeholder Impact

• Shareholders: May observe the insider sale and consider its implications, though the 10b5-1 plan context typically lessens concerns.

Key Dates

Keywords

Theravance Biopharma, TBPH, Form 4, Insider Sale, Rhonda Farnum, 10b5-1 Plan, Stock Transaction, Beneficial Ownership